ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-OR083

Combination Therapy of Empagliflozin and Linagliptin vs. Metformin and Insulin Glargine on Intra- and Renal Hemodynamics in Type 2 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Ott, Christian, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  • Kannenkeril, Dennis, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  • Jung, Susanne, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  • Schmieder, Roland E., Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Combination of insulin with oral antidiabetic drugs is a valid option, but oral combination therapy emerged as an alternative treatment in type 2 diabetes (T2DM). However, the intra-, and renal hemodynamic profile of such combinations therapies has not been evaluated so far.


In this study 101 patients with T2DM were randomized to receive either empagliflozin 10mg and linagliptin 5mg (E+L group) orally or metformin and insulin glargine (M+I group, with dose adjustments according to glucose levels), for 3 months. Renal hemodynamics were assessed with the “gold-standard”, namely constant-infusion input-clearance technique with para-aminohippuric acid and inulin for renal plasma flow (RPF) and glomerular filtration rate (GFR). Intrarenal hemodynamics were calculated according the model established by Gomez.


Due to the multiple dose adjustment of insulin glargine, reduction in HbA1c was greater in M+I than in E+L group (p=0.001), hence all analyses between M+I and E+L were HbA1c-adjusted to evaluate the glucose independent effects between the 2 therapies. In E+L group, body weight (p<0.001), body mass index (p<0.001) and both ambulatory 24-h systolic and diastolic BP (p=0.004/0.036) were reduced compared to M+I group.
Treatment with E+L reduced GFR (127±13 vs. 120±14 ml/min, p=0.003), but RPF remained unchanged (623±114 vs. 615±115 ml/min, p=0.536). In contrast, treatment with M+I not only reduced GFR (127±15 vs. 120±13 ml/min, p=0.001), but also resulted in a significant reduction of RPF (653±150 vs. 600±121 ml/min, p<0.001) that was different between the 2 groups (p<0.001). Analysis of intrarenal hemodynamics revealed that E+L did not significantly impact on resistance of afferent arteriole (RA) (p=0.116), but diminished resistance of efferent arteriole (RE) (p=0.001), whereas in M+I group RA was reduced (p=0.006) and RE remained unchanged (p=0.538). Thus, the effects on RA (p<0.001) and on RE (p<0.001) were significantly different between the 2 groups.


As expected combination therapy with E+L reduced GFR, whereas M+I resulted in both reduction of GFR and RPF. Analysis of intrarenal hemodynamics identified different underlying hemodynamic mechanism, with E+L (surprisingly) mainly decreasing RE and M+I affecting RA.


  • Commercial Support – Boehringer Ingelheim